Preventing kidney injury in children with neurogenic bladder dysfunction

International Journal of Preventive Medicine

Volumn 4, Issue 12, 2013, Pages 1359-1364

  Javadi Larijani, Faezeh ^a   Moghtaderi, Mastaneh ^a   Hajizadeh, Nilofar ^a   Assadi, Farahnak ^b  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b RUSH UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Anticholinergic; Botulinum toxin; Chronic kidney failure; Clean intermittent catheterization; Neurogenic bladder dysfunction

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANTIBIOTIC AGENT; BOTULINUM TOXIN A; CHOLINERGIC RECEPTOR BLOCKING AGENT; CREATININE; OXYBUTYNIN; PROPIVERINE; TOLTERODINE; TRICYCLIC ANTIDEPRESSANT AGENT; TROSPIUM CHLORIDE;

ARTICLE; CARDIOVASCULAR DISEASE; CHILD; CREATININE BLOOD LEVEL; CYSTOGRAPHY; DETRUSOR DYSSYNERGIA; EARLY DIAGNOSIS; ECHOGRAPHY; HUMAN; HYDRONEPHROSIS; INTERMITTENT CATHETERIZATION; KIDNEY INJURY; MENINGOMYELOCELE; NEUROGENIC BLADDER; OVERACTIVE BLADDER; PATHOPHYSIOLOGY; RESIDUAL URINE; SACRAL NERVE STIMULATION; SPINAL DYSRAPHISM; SYSTEMIC DISEASE; URINARY TRACT INFECTION; URODYNAMICS; VESICOURETERAL REFLUX;

EID: 84890853956     PISSN: 20087802     EISSN: 20088213     Source Type: Journal    
DOI: None     Document Type: Article

References (45)

1. Mourtzinos A, Stoffel JT. Management goals for the spina bifida neurogenic bladder: A review from infancy to adulthood. Urol Clin North Am 2010;37:527-535.
2. Frimberger D, Cheng E, Kropp BP. The current management of the neurogenic bladder in children with spina bifida. Pediatr Clin North Am 2012;59:757-767.
3. Amarante MA, Shrensel JA, Tomei KL, Carmel PW, Gandhi CD. Management of urological dysfunction in pediatric patients with spinal dysraphism: Review of the literature. Neurosurg Focus 2012;33:E4.
4. Bauer SB. Neurogenic bladder: Etiology and assessment. Pediatr Nephrol 2008;23:541-551.
5. Rothenberg SP, da Costa MP, Sequeira JM, Cracco J, Roberts JL, Weedon J, et al. Autoantibodies against folate receptors in women with a pregnancy complicated by a neural-tube defect. N Engl J Med 2004;350:134-142.
6. Shin M, Kucik JE, Siffel C, Lu C, Shaw GM, Canfield MA, et al. Improved survival among children with spina bifida in the United States. J Pediatr 2012;161:1132-1137.
7. Satar N, Bauer SB, Scott RM, Shefner J, Kelly M, Darbey M. Late effects of early surgery on lipoma and lipomeningocele in children less than 1 year old. J Urol 1997;157:1434-1437.
8. Kari JA. Neuropathic bladder as a cause of chronic renal failure in children in developing countries. Pediatr Nephrol 2006;21:517-520.
9. Filler G, Gharib M, Casier S, Lödige P, Ehrich JH, Dave S. Prevention of chronic kidney disease in spina bifida. Int Urol Nephrol 2012;44:817-827.
10. Lehnert T, Weisser M, Till H, Rolle U. The effects of long-term medical treatment combined with clean intermittent catheterization in children with neurogenic detrusor overactivity. Int Urol Nephrol 2012;44:335-341.
11. Verpoorten C, Buyse GM. The neurogenic bladder: Medical treatment. Pediatr Nephrol 2008;23:717-725.
12. Himsl KK, Hurwitz RS. Pediatric urinary incontinence. Urol Clin North Am 1991;18:283-293.
13. Edelstein RA, Bauer SB, Kelly MD, Darbey MM, Peters CA, Atala A, et al. The long-term urological response of neonates with myelodysplasia treated proactively with intermittent catheterization and anticholinergic therapy. J Urol 1995;154:1500-1504.
14. Lavallée LT, Leonard MP, Dubois C, Guerra LA. Urodynamic testing - Is it a useful tool in the management of children with cutaneous stigmata of occult spinal dysraphism? J Urol 2013;189:678-683.
15. Drzewiecki BA, Bauer SB. Urodynamic testing in children: Indications, technique, interpretation and significance. J Urol 2011;186:1190-1197.
16. Bauer SB, Hallett M, Khoshbin S, Lebowitz RL, Winston KR, Gibson S, et al. Predictive value of urodynamic evaluation in newborns with myelodysplasia. JAMA 1984;252:650-652.
17. Sarica K, Erbaǧci A, Yaǧci F, Yurtseven C, Buyukbebeci O, Karakurum G. Multidisciplinary evaluation of occult spinal dysraphism in 47 children. Scand J Urol Nephrol 2003;37:329-334.
18. Bauer SB, Joseph DB. Management of the obstructed urinary tract associated with neurogenic bladder dysfunction. Urol Clin North Am 1990;17:395-406.
19. Bauer SB, Labib KB, Dieppa RA, Retik AB. Urodynamic evaluation of boy with myelodysplasia and incontinence. Urology 1977;10:354-362.
20. Perez LM, Khoury J, Webster GD. The value of urodynamic studies in infants less than 1 year old with congenital spinal dysraphism. J Urol 1992;148:584-587.
21. Seki N, Akazawa K, Senoh K, Kubo S, Tsunoda T, Kimoto Y, et al. An analysis of risk factors for upper urinary tract deterioration in patients with myelodysplasia. BJU Int 1999;84:679-682.
22. Joseph DB. The effect of medium-fill and slow-fill saline cystometry on detrusor pressure in infants and children with myelodysplasia. J Urol 1992;147:444-446.
23. Kessler TM, Lackner J, Kiss G, Rehder P, Madersbacher H. Early proactive management improves upper urinary tract function and reduces the need for surgery in patients with myelomeningocele. Neurourol Urodyn 2006;25:758-762.
24. Guys JM, Hery G, Haddad M, Borrionne C. Neurogenic bladder in children: Basic principles, new therapeutic trends. Scand J Surg 2011;100:256-263.
25. Madersbacher H. Neurogenic bladder dysfunction in patients with myelomeningocele. Curr Opin Urol 2002;12:469-72.
26. Baskin LS, Kogan BA, Benard F. Treatment of infants with neurogenic bladder dysfunction using anticholinergic drugs and intermittent catheterisation. Br J Urol 1990;66:532-534.
27. Buyse G, Verpoorten C, Vereecken R, Casaer P. Intravesical application of a stable oxybutynin solution improves therapeutic compliance and acceptance in children with neurogenic bladder dysfunction. J Urol 1998;160:1084-1087.
28. Amark P, Bussman G, Eksborg S. Follow-up of long-time treatment with intravesical oxybutynin for neurogenic bladder in children. Eur Urol 1998;34:148-153.
29. Haferkamp A, Staehler G, Gerner HJ, Dörsam J. Dosage escalation of intravesical oxybutynin in the treatment of neurogenic bladder patients. Spinal Cord 2000;38:250-254.
30. Buyse G, Waldeck K, Verpoorten C, Björk H, Casaer P, Andersson KE. Intravesical oxybutynin for neurogenic bladder dysfunction: Less systemic side effects due to reduced first pass metabolism. J Urol 1998;160:892-896.
31. Husmann DA. Use of sympathetic alpha antagonists in the management of pediatric urologic disorders. Curr Opin Urol 2006;16:277-282.
32. Dyer LL, Franco I. Botulinum Toxin-A therapy in pediatric urology: Indications for the neurogenic and non-neurogenic neurogenic bladder. Scientific World Journal 2009;9:1300-1305.
33. Pascali MP, Mosiello G, Boldrini R, Salsano ML, Castelli E, De Gennaro M. Effects of botulinum toxin type a in the bladder wall of children with neurogenic bladder dysfunction: A comparison of histological features before and after injections. J Urol 2011;185:2552-2557.
34. Watanabe JH, Campbell JD, Ravelo A, Chancellor MB, Kowalski J, Sullivan SD. Cost analysis of interventions for antimuscarinic refractory patients with overactive bladder. Urology 2010;76:835-840.
35. Riccabona M, Koen M, Schindler M, Goedele B, Pycha A, Lusuardi L, et al. Botulinum-A toxin injection into the detrusor: A safe alternative in the treatment of children with myelomeningocele with detrusor hyperreflexia. J Urol 2004;171:845-848.
36. Joseph DB. Current approaches to the urologic care of children with spina bifida. Curr Urol Rep 2008;9:151-157.
37. de Jong TP, Chrzan R, Klijn AJ, Dik P. Treatment of the neurogenic bladder in spina bifida. Pediatr Nephrol 2008;23:889-896.
38. Guys JM, Breaud J, Hery G, Camerlo A, Le Hors H, De Lagausie P. Endoscopic injection with polydimethylsiloxane for the treatment of pediatric urinary incontinence in the neurogenic bladder: Long-term results. J Urol 2006;175:1106-1110.
39. Lottmann HB, Margaryan M, Bernuy M, Grosz A, Aigrain Y, Lortat-Jacob S, et al. Long-term effects of dextranomer endoscopic injections for treatment of urinary incontinence: An update of a prospective study of 31 patients. J Urol 2006;175:1485-1489.
40. Snodgrass W, Barber T. Comparison of bladder outlet procedures without augmentation in children with neurogenic incontinence. J Urol 2010;184:1775-1780.
41. Churchill BM, Bergman J, Kristo B, Gore JL. Improved continence in patients with neurogenic sphincteric incompetence with combination tubularized posterior urethroplasty and fascial wrap: The lengthening, narrowing and tightening procedure. J Urol 2010;184:1763-1767.
42. Metcalfe PD, Rink RC. Bladder augmentation: Complications in the pediatric population. Curr Urol Rep 2007;8:152-6.
43. Lordêlo P, Teles A, Veiga ML, Correia LC, Barroso U Jr. Transcutaneous electrical nerve stimulation in children with overactive bladder: A randomized clinical trial. J Urol 2010;184:683-689.
44. Haddad M, Besson R, Aubert D, Ravasse P, Lemelle J, El Ghoneimi A, et al. Sacral neuromodulation in children with urinary and fecal incontinence: A multicenter, open label, randomized, crossover study. J Urol 2010;184:696-701.
45. Atala A. Tissue engineering of human bladder. Br Med Bull 2011;97:81-104.